Arbutus Biopharma (ABUS) EPS (Weighted Average and Diluted) (2013 - 2026)
Arbutus Biopharma's (ABUS) quarterly EPS (Weighted Average and Diluted) came in at $0.87 in Q1 2026, up 769.23% year-on-year from $0.1 in Q1 2025, and up 8800.0% quarter-over-quarter from -$0.01 in Q4 2025.
Arbutus Biopharma (ABUS) EPS (Weighted Average and Diluted) (2013 - 2026) Analysis & Trends
Arbutus Biopharma has disclosed EPS (Weighted Average and Diluted) across 13 years of filings, most recently posting $0.87 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.87, up 769.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.83 (up 302.44% YoY), and the FY2025 annual result was -$0.17, up 55.26% from the prior year.
- EPS (Weighted Average and Diluted) came in at $0.87 for Q1 2026 at Arbutus Biopharma, up from -$0.01 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.87 in Q1 2026 to a low of -$0.14 in Q4 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.1 (2022), against an average of -$0.03.
- Across the five-year window, EPS (Weighted Average and Diluted) slumped 30.0% in 2025 and soared 769.23% in 2026, its largest moves.
- Arbutus Biopharma's EPS (Weighted Average and Diluted) stood at -$0.14 in 2022, then rose by 14.29% to -$0.12 in 2023, then jumped by 41.67% to -$0.07 in 2024, then jumped by 85.71% to -$0.01 in 2025, then surged by 8800.0% to $0.87 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.87 (Q1 2026), -$0.01 (Q4 2025), and -$0.04 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Arbutus Biopharma | 882.62 Mn | 882.62 Mn | - | 0.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.87 |
| Dec 31, 2025 | -0.01 |
| Sep 30, 2025 | -0.04 |
| Jun 30, 2025 | 0.01 |
| Mar 31, 2025 | -0.13 |
| Dec 31, 2024 | -0.07 |
| Sep 30, 2024 | -0.10 |
| Jun 30, 2024 | -0.11 |
| Mar 31, 2024 | -0.10 |
| Dec 31, 2023 | -0.12 |
| Sep 30, 2023 | -0.12 |
| Jun 30, 2023 | -0.10 |
| Mar 31, 2023 | -0.10 |
| Dec 31, 2022 | -0.14 |
| Sep 30, 2022 | -0.12 |
| Jun 30, 2022 | -0.10 |
| Mar 31, 2022 | -0.11 |
| Dec 31, 2021 | -0.15 |
| Sep 30, 2021 | -0.24 |
| Jun 30, 2021 | -0.23 |